24/7 Market News Snapshot 25 August, 2025 – Biofrontera Inc. Common Stock (NASDAQ:BFRI)

August 25, 2025

DENVER, Colo., 25 August, 2025 (www.247marketnews.com) – (NASDAQ:BFRI) are discussed in this article.
Biofrontera Inc. is currently witnessing a robust resurgence in the pre-market session, trading at $1.135—an impressive increase of 17.78% from its previous close of $0.964. This positive movement showcases substantial buying interest, underscored by a trading volume of 2.59 million shares. Analysts suggest that technical indicators may reflect increasing momentum, with potential resistance levels at prior highs, while support may be seen around $1.00. Continued observation of volume patterns and overall market sentiment will be essential for gauging the sustainability of this upward trend, as heightened volatility could accompany the current bullish sentiment.

In addition to its market performance, Biofrontera has achieved a major milestone by completing patient enrollment in its Phase 2b clinical trial for Ameluz®, aimed at addressing moderate to severe acne vulgaris. This randomized, double-blind, multicenter study evaluates the efficacy of Ameluz®, utilizing red-light photodynamic therapy (PDT) to target both inflammatory and non-inflammatory acne lesions. The trial’s participants will continue to be monitored for results, with top-line data anticipated in the first quarter of 2026.

Dr. Hermann Luebbert, the company’s CEO and Chairman, expressed enthusiasm for this crucial achievement, emphasizing Biofrontera’s dedication to enhancing treatment options for individuals affected by acne. With over 50 million Americans facing this condition annually, there exists a pressing need for alternatives to existing therapies, which often carry significant side effects and limitations.

Looking ahead, Biofrontera is strategizing to engage with the U.S. Food and Drug Administration (FDA) in early Q3 2026 regarding the potential for a Phase 3 program, contingent on favorable trial outcomes. The excitement surrounding Ameluz® is echoed by Dr. Mitchel P. Goldman, one of the study’s coordinating investigators, who highlighted the promise of PDT in improving acne treatment outcomes. Biofrontera remains committed to pioneering novel therapeutic solutions in dermatology, positioning Ameluz® as a key player in the evolution of acne treatment strategies.

Related news for (BFRI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.